Engineering the end of treatment resistance
A multi-modal AI engine that predicts how diseases evolve resistance, from the molecular mechanisms driving it to the clinical outcomes that follow.
Evolution is outpacing
innovation.
Pathogens acquire resistance to frontline therapies while tumors adapt through immune evasion and genetic diversification. These dynamics are driven by complex interactions between microbial genomes, tumor cells, host immunity, and both personal and environmental factors.
It takes over a decade and billions of dollars to bring a new therapy to market. It takes biology far less time to find a way around it. The fallout spans the entire system: patients lose viable treatment options, drug developers watch billion-dollar programs fail to outcomes that were biologically predictable, and diagnostics struggle to keep pace with the resistance patterns emerging around them.
How our engine works.
Built on the principle that context is everything in biology. Instead of running multi-omics on everything and letting AI sort it out, our engine pairs the right models with the right data to answer the questions that actually move drug development and diagnostics forward.
Foundation Layer
Learns the structure, constraints, and relationships embedded in biological systems, from pathogen genomes to host immunity. Discovers resistance mechanisms and adaptive trajectories that conventional tools miss, because they lack the biological context to look for them.
Applied Intelligence Layer
Translates foundational understanding into task-specific outputs for drug development and diagnostics. Each model is purpose-built for a defined decision point, not repurposed from a general pipeline, so the output is interpretable, mechanism-aware, and directly actionable.
Our philosophy
Context is everything in biology. Meaningful signal lives in the relationship between the right data types, captured at the right resolution, for a precisely defined biological or clinical question. Breadth of biological data that captures rich contextual information is equally if not more important than data scale. Therefore, the future of AI in biology belongs to teams that bridge the divide between wet-lab and dry-lab, where data generation and modeling are intertwined.
Intera Bio is a member of theNVIDIA Inception program
© 2026 NVIDIA, the NVIDIA logo, and NVIDIA Inception are trademarks and/or registered trademarks of NVIDIA Corporation in the U.S. and other countries.
Intelligence at the decision points that matter.
Our engine delivers high-impact outputs across drug development pipelines and diagnostic innovation, wherever therapeutic resistance and immune adaptation shape outcomes.
Resistance Mechanism Discovery
Uncover the genomic and transcriptomic drivers of drug resistance, including mechanisms invisible to sequence databases, to de-risk preclinical pipelines and identify novel targets.
Target Identification & Validation
Surface drug and vaccine targets informed by how pathogens and tumors actually behave under therapeutic pressure, not just what their genomes encode at rest.
Diagnostic Biomarker Development
Identify biomarkers for resistant phenotypes that translate into next-generation molecular diagnostics, moving beyond cataloging known mutations to predicting emergent resistance.
Preclinical Pipeline De-risking
Predict which compounds are most likely to face resistance, how quickly, and through which mechanisms, before expensive late-stage failures make those answers obvious.
The old playbook has hit its ceiling.
For decades, the response to therapeutic resistance has been the same: culture a pathogen, test a drug, catalog the result. That approach is hitting diminishing returns. Three shifts are converging to change what's possible.
Regulatory Momentum
Regulatory bodies are signaling a shift toward computational models and new approach methodologies as part of the path to bringing safe, effective drugs to market. The window for AI-native platforms is opening.
The Wet-Lab / Dry-Lab Plateau
Falling sequencing costs make multi-modal data generation practical, but data alone isn't the bottleneck. The real gap is in teams that can bridge wet-lab biology and computational modeling, where data generation and insight are a single loop rather than separate disciplines.
A Growing Crisis, A Broken Market
Therapeutic resistance is recognized as one of the defining challenges in modern medicine, yet the economic incentives for new therapies remain misaligned. This mismatch creates urgent demand for technologies that de-risk and accelerate the path to approval.
Enter where the ground truth is cleanest. Scale with confidence.
Every AI model is only as good as the assay that produces its training data. Our expansion follows one rule: enter each disease area where a gold-standard, quantitative, in vitro assay exists that directly guides drug development decisions.
We start with infectious disease, where the assays are the tightest, the benchmarks are the clearest, and our approach covers the most ground. Each phase builds capabilities and validates engine components that carry directly into the next.
Antimicrobial Resistance
Small-molecule antibiotics, resistance prediction, diagnostic biomarkers, and novel target discovery. Non-dilutive capital available through biosecurity and non-profit initiatives.
Antivirals, Biologics & Vaccines
Evolutionary challenges shift from pharmacological resistance to immune evasion. Host-based integration designed to capture exactly this distinction.
Oncology
Same engine architecture, scaled complexity. Checkpoint inhibitors, ADCs, and targeted small molecules all face multi-modal adaptive resistance.
Biology doesn't wait.
Neither should we.
We pair computational resistance prediction with translational profiling services, so every engagement generates the insight and the data to make the next one sharper. If you're a researcher, biopharma partner, or investor, we'd love to talk.